A long non-coding RNA in early and late-stage breast cancer as a prognostic marker, diagnostic marker, and therapeutic target.

— Technology Description

Researchers in Dr. Jessica Silva-Fisher’s laboratory have developed antisense oligonucleotide targeting a long non-coding RNA (lncRNA), LINC00355, as a treatment for late-stage relapse (LSR) breast cancer. LINC00355 is highly expressed in LSR breast cancer patients and…

Paper-Based Assays for Primary Hemostasis and Thrombosis

— Paper-Based Assays for Primary Hemostasis and Thrombosis

Technology Description

Researchers in Dr. David Bark’s laboratory at Washington University have developed a method that allows for the evaluation of various flow-dependent pathways of hemostasis on microfluidic paper-based analytical d…

Mutant PDGF-B as a VEGFR inhibitor

— Technology Description

Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesi…

Create a Collection
Creating...